35 citations
,
March 2010 in “Journal of Dermatological Science” Ebastine may help regrow hair in alopecia areata patients.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
5 citations
,
July 2007 in “PubMed” An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
November 2025 in “Clinical and Translational Allergy” The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
January 1988 in “Inpharma (Balgowlah)” New retinoids are effective for various skin conditions and are being developed to have fewer side effects.
September 2017 in “Pediatric Dermatology” The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
March 2012 in “Reactions Weekly” A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
37 citations
,
August 2011 in “Journal of Bone and Mineral Research” A girl had rickets due to a gene mutation affecting vitamin D response.
5 citations
,
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” The gene therapy showed significant wound healing and was safe for treating severe RDEB.
1 citations
,
January 2005 in “Side effects of drugs annual” The document concluded that various dermatological treatments have different effectiveness and side effects, with some causing irritation, allergic reactions, or systemic effects.
17 citations
,
August 2012 in “Journal of Medical Genetics” A new mutation in the XEDAR gene might cause a rare skin condition called hypohidrotic ectodermal dysplasia.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
January 2019 in “Springer eBooks” Modified HDL can better deliver drugs and genes, potentially improving treatments and reducing side effects.
May 2018 in “Dermatologic Surgery”
March 2026 in “Preprints.org” DRDE-07 shows promise for treating skin diseases due to its favorable properties.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
21 citations
,
September 2019 in “International Journal of Nanomedicine” RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.